Cashu Finance
  • Terminal
  • Stocks
  • Spotlight
  • Research
Log inSign Up
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. FEMY

Market Cap: $8.39M

FI

Femasys Inc.

FEMY
NASDAQ (NASDAQ Capital Market)USD
Purchase FEMY
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutivePatentsEarnings Surprise
Cashu Finance

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

StocksAboutAdvertisersBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

–
USD
–(–)

Open

$4.205

Prev. Close

$2.74

High

$4.56

Low

$4.205

Company Profile

Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.

CEOKathy Lee-Sepsick
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees53
IPO DateJun 18, 2021
ExchangeNASDAQ
Exchange NameNASDAQ Capital Market
CurrencyUSD
Headquarters & Contact
Address3950 Johns Creek Court
City / State / ZIPSuwanee, GA, 30024
CountryUnited States
Phone770 500 3910
Websitehttps://www.femasys.com

Recently from Cashu